USC and SERGAS. Anti-CD26 antibodies as biomarkers of autoimmune and/or inflammatory diseases

USC and SERGAS. Anti-CD26 antibodies as biomarkers of autoimmune and/or inflammatory diseases[line_break]P 201630620

Project Description

The research group formed by members of the USC and the Servizo Galego de Saúde, are holders of the patent 201630620 whose objective is the use of anti-CD26 antibody levels as autoimmune and/or inflammatory biomarkers of diseases.

A kit is presented to detect a new serum biomarker with screening, diagnostic and monitoring potential. Potential in the prognosis and to delineate those who respond to biological therapies (precision medicine) and other inflammatory diseases.

You can consult the patent description sheet.

Description of the Area of Activity / Technology

Rheumatoid arthritis (RA) is considered an autoimmune and inflammatory disease. It is the most common form of chronic inflammatory joint disease and affects 1-2% of the general population. There is no perfect biomarker for screening, diagnosis, precision medicine or monitoring of RA.

If this offer is of interest to you or you need more information about it, please contact us. This offer can take the form of a «Partnership Agreement» to adapt this technology to your areas of research, or a «License Agreement» to use this patent directly.